Lomitapide
Orphan DrugFDA Approved
Description
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including apheresis, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). It is used to treat familial dysbetalipoproteinemia.
Indications & Therapeutic Use
Homozygous Familial Hypercholesterolemia, Familial Dysbetalipoproteinemia
Linked Diseases:
Global Availability (4 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Lomitapide
| Generic Name | Lomitapide |
| Brands | 1 brand available |
| Active Ingredient | Lomitapide |
| Drug Class | Homozygous Familial Hypercholesterolemia |
| Manufacturer | Aegerion Pharmaceuticals |
| Dosage Forms | Capsule |
| Medical Code | C10AX12 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved |
| Countries | 4 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations5 Validated Nodes